Keenova Therapeutics plc: auditor change — Mallinckrodt plc dismisses Deloitte as auditor, appoints PwC

Keenova Therapeutics plc

Dismissed Deloitte & Touche effective April 3, 2024; engaged PricewaterhouseCoopers for FY ending Dec 27, 2024.
No disagreements with Deloitte of the type under Item 304(a)(1)(iv) during audit periods or through April 3, 2024.
No reportable events under Item 304(a)(1)(v) occurred during same periods.
Deloitte's audit reports on prior financials contained no adverse opinion or qualification.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Keenova Therapeutics plc dismissed Deloitte & Touche LLP as its auditor.

Action: dismissal
Auditor: Deloitte & Touche LLP
Successor: PricewaterhouseCoopers LLP

Exact text from the filing

result of this process, on April 3, 2024, upon the recommendation of the Audit Committee, the Board approved the dismissal of Deloitte & Touche LLP (“ Deloitte ”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Keenova Therapeutics plc engaged PricewaterhouseCoopers LLP as its auditor.

Action: engagement
Auditor: PricewaterhouseCoopers LLP

Exact text from the filing

Also, on April 3, 2024, the Audit Committee approved the engagement of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 27, 2024, effective immediately.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001104659-24-044766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.